Uncategorized
Inotek to re-evaluate utility of trabodenoson in glaucoma treatment
Trabodenoson added to latanoprost in a fixed-dose treatment for glaucoma yielded “no meaningful clinical advantage” in a phase 2 trial, according to an Inotek Pharmaceuticals press release.The randomized, double-masked, dose-ranging trial compared combinations of trabodenoson at 3% and 6% and latanoprost at 0.005% and 0.0025% with latanoprost alone for reducing IOP in patients with ocular hypertension or primary open-angle glaucoma. The study period was 8 weeks.